Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25502491 | 0.90 | HRH3 (0.36) | HRH3NPC1SMN1; SMN2KDM1ACARM1 | |
| SCHEMBL25828607 | 0.85 | NPC1 (0.33) | NPC1ALDH1A1TSHRKDM1ABCHE | |
| SCHEMBL24673651 | 0.85 | HRH3 (0.40) | HRH3NPC1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL19655526 | 0.82 | TSHR (0.32) | ALDH1A1MAPTTSHR | |
| SCHEMBL23945284 | 0.81 | HRH3 (0.36) | HRH3NPC1SMN1; SMN2CARM1PRMT6 | |
| SCHEMBL22793895 | 0.80 | HRH3 (0.42) | HRH3NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12448064 | 0.78 | HRH3 (0.37) | HRH3ALDH1A1MAPTSMN1; SMN2KDM1A | |
| SCHEMBL24764415 | 0.78 | NPC1 (0.35) | HRH3NPC1SMN1; SMN2CARM1PRMT6 | |
| SCHEMBL24764431 | 0.76 | NPC1 (0.34) | HRH3NPC1ALDH1A1SMN1; SMN2CARM1 | |
| SCHEMBL24763610 | 0.76 | HRH3 (0.33) | HRH3NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885NPC1 3159/4885ALDH1A1 2776/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | HRH3 3052/4885NPC1 3895/4885ALDH1A1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.